BioCryst reports Q4 EPS (20c), consensus (15c)
Reports Q4 revenue $3.9M, consensus $4.9M. Decrease in revenue compared to prior year was primarily due to the recognition of $2.3M of RAPIVAB product sales to commercial partners in 2016 that did not recur in 2017 and approximately a $2.5M decline in collaborative revenue in 2017, associated with a decrease in development activity under U.S. Government development contracts. "Enrollment in the 750 mg cohort of the Zenith-1 proof-of-concept Phase 2 clinical trial of a liquid formulation of BCX7353 for treatment of acute angioedema attacks in HAE has been completed and the 500 mg cohort is currently enrolling. We expect to report top-line results from the first cohort in the second half of 2018...The company's optimized lead candidates, BCX9250 and BCX9499, are projected to enter Phase 1 clinical trials during the first half of 2019," BioCryst said.